Please use this identifier to cite or link to this item:
|Title:||Peginesatide for maintenance treatment of Anemia in hemodialysis and nondialysis patients previously treated with Darbepoetin Alfa||Authors:||Fishbane, Steven ;Roger, Simon D ;Martin, Edward ;Runyan, Grant ;O'Neil, Janet ;Qiu, Ping ;Locatelli, Francesco||Issue Date:||Apr-2013||Source:||Volume 8, Issue 4, pp. 538-545||Journal title:||Clinical journal of the American Society of Nephrology||Abstract:||Background and objectives Peginesatide (Omontys) is a novel, synthetic, PEGylated, peptide-based erythropoiesis stimulating agent (ESA) that is designed to specifically stimulate the erythropoietin receptor. This study evaluated maintenance of hemoglobin levels in patients after conversion from darbepoetin alfa to once-monthly peginesatide. Design, setting, participants, & measurements. This open-label, multicenter study included 101 CKD patients, 52 of whom were receiving dialysis. The duration of the study was 24 weeks. The primary endpoint was the mean change in hemoglobin from baseline to the evaluation period (weeks 19–24). The study was conducted during the period from September 22, 2008 to December 24, 2009. Results The mean change among hemodialysis patients was –0.42 g/dl (95% confidence interval, –0.65 to –0.19) and the mean change among CKD nondialysis patients was 0.49 g/dl (95% confidence interval, 0.26–0.71). The percentages of patients who maintained hemoglobin levels within 61.0 g/dl of baseline values were as follows: 80.0% for hemodialysis and 68.1% for nondialysis, and 73.3% for hemodialysis and 68.1% for nondialysis within the target range of 10.0–12.0 g/dl. Few patients received red blood cell transfusions (hemodialysis, 5.8%; non- dialysis, 2.0%). Seventy-nine patients experienced adverse events, the majority of which were mild or moderate in severity. There were 40 serious adverse events and 2 deaths reported. Conclusions In this study, once-monthly peginesatide resulted in a slight decrease in mean hemoglobin levels in individuals on hemodialysis and a small increase in individuals with CKD who were not on dialysis.||Description:||Open Access: http://cjasn.asnjournals.org/content/8/4/538.short||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/144||DOI:||10.2215/CJN.03440412||Pubmed:||http://www.ncbi.nlm.nih.gov/pubmed/23243269||ISSN:||1555-905X||Publicaton type:||Journal Article||Keywords:||Kidney Disease
|Study or Trial:||Clinical Trial|
|Appears in Collections:||Renal Medicine|
Show full item record
checked on Feb 5, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.